India has been traditionally quite strong in the pharma sector, with a low cost of manufacturing (30%–35% lower than in the US and Europe), cost-efficient R&D (about 87% less than in developed markets ...

This is according to a report recently released by consultancy Evaluate, which analyses trends in the pharmaceutical sector. Worldwide cancer drug sales are already way ahead of those of other drugs ...